strontium/breast neoplasms

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 69 rezilta yo

Radiosensitizing effects of arsenic trioxide on MCF-7 human breast cancer cells exposed to 89 strontium chloride.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The aim of this study was to investigate the radiosensitizing effects of arsenic trioxide (As2O3) on MCF-7 human breast cancer cells irradiated with 89 strontium chloride (89SrCl2). The 50% inhibitory concentration (IC50) was calculated from results of an MTT assay. The concentration of As2O3 less

Urinary strontium and the risk of breast cancer: a case-control study in Guangzhou, China.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Strontium has been widely used in industries like electronic and pharmacy. It has a carcinogenic potential, however, and no study has been conducted to evaluate its effects on cancer risk. The aim of this study was to explore the possible association between strontium and breast cancer risk in a

Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Strontium-89 chloride is a radiopharmaceutical that localizes to actively forming new bone, such as metastatic bone lesions from prostate and breast cancer. It provides effective systemic endo-osseous local radiation therapy to these painful lesions. Strontium-89 will soon be available to physicians

Strontium-89 chloride in the treatment of bone metastases from breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Sixty-four patients with painful metastatic breast cancer in bone were treated with 2 MBq/kg of strontium-89 chloride as a single intravenous injection. Patients were followed with records of medication, hematology parameters, serial bone and Sr-89 bremsstrahlung images and with a point pain score

Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Two hundred and two patients with bone pain from metastatic cancer were treated with 40 microCi/kg of Sr-89. Patients were followed with pain diaries, records of medication taken, sleep patterns, serial bone scans and a Karnofsky Index. One hundred and thirty-seven patients with adequate followup

Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Most studies of prostate cancer have shown that strontium-89 chloride (89Sr) is effective in the palliation of metastatic bone pain, refractory to conventional analgesia. The aim of this study was to evaluate the usefulness of 89Sr for bone pain palliation in breast cancer patients. Forty women were

Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Fifteen patients with breast cancer and skeletal metastases who had bone pain refractory to opioid analgesics and who were not eligible for or had not responded to local field radiotherapy, were treated with strontium-89. All patients had received previous treatment with chemotherapy and

[Effectiveness of Strontium-89 for Neuropathic Pain Caused by Bone Metastases from Breast Cancer: A Case Report].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The patient was a 47-year-old female with stage IV breast cancer and multiple bone metastases. She received various systemic therapies (hormone therapy and chemotherapy) and underwent mastectomy between 2013 and 2018; in the beginning of 2018, she started experiencing bone metastatic pain in the

Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We have used strontium-89 chloride (89Sr) for the palliative treatment of metastatic bone pain. Seventy-six patients (50 males with prostate carcinoma and 26 females with breast cancer) were treated with 148 MBq of 89Sr. Sixteen patients were retreated, receiving two or three doses; the total number

Tumor regression of multiple bone metastases from breast cancer after administration of strontium-89 chloride (Metastron).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We report a case of tumor regression of multiple bone metastases from breast carcinoma after administration of strontium-89 chloride. This case suggests that strontium-89 chloride can not only relieve bone metastases pain not responsive to analgesics, but may also have a tumoricidal effect on bone

Clinical experience with strontium-89 in prostatic and breast cancer patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Bone metastases are a major problem in the clinical management of patients with breast or prostate cancer. Severe bone pain can be a particularly debilitating effect of metastatic disease, resulting in a growing dependency on opioid analgesics and a reduced quality of life in patients who have a

Systemic radionuclide therapy with strontium chloride Sr 89 for painful skeletal metastases in prostate and breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Systemic radionuclide therapy with strontium chloride Sr 89 is a rediscovered alternative to relieve pain from bony metastases. Although numerous advances have been made in the diagnosis and treatment of cancer, pain remains a serious and debilitating disease complication. An increasing number of

Experience with 89-strontium treatment of painful osseous metastases from breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[Breast Cancer Patient with Bone Metastases Who Was Able to Return Home without Using Opioids after Administration of Strontium-89 Chloride].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 46-year-old woman underwent mastectomy for right inflammatory breast cancer.Three years later, she was diagnosed with multiple bone metastases and was treated with systemic chemotherapy and zoledronic acid.Six years after the mastectomy, she complained of severe sacral pain, and 40 Gy external

Pain palliative therapy in women with breast cancer osseous metastatic disease and the role of specific serum cytokines as prognostic factors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To evaluate the efficacy of radionuclide palliative therapy (RPT) in women suffering from painful metastatic bone disease (MBD) due to breast cancer (BrCa), and to investigate the possible relationship between the RPT efficacy and cytokines levels. METHODS Sixty-three BrCa women patients

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye